// App-Quantinova.ai

: A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Mariona Calvo

Principal Investigators

  • Konstantin Penkov

  • Alexander I. Spira

  • Irene Moreno Candilejo

  • Neal D. Shore

  • Tian Zhang

  • Begoña Mellado-Gonzalez

  • Teresa Alonso Gordoa

  • Luis Paz-Ares Rodriguez

  • Stefano R. Tarantolo

  • Juan José Soto

  • Robert S. Alter

  • Claudia Andreu-Vieyra

  • Timothy Bowler

  • Arnab K Maity

  • Subramanian Hariharan

  • Michael Thomas Schweizer

Medical Centers

  • Division of Medical Oncology, University of Washington Seattle, WA, USA and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA

  • Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

  • Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain

  • Hackensack University Medical Center, Oradell, NJ

  • Division of Medical Oncology, START Madrid-HM Sanchinarro CIOCC Early Phase Program, Medical University Hospital of Sanchinarro, Madrid, Spain

  • PHI “Clinical Hospital RZhD-Medicine St.Petersburg”, St. Petersburg, Russian Federation

  • Virginia Cancer Specialists, Fairfax, VA

  • Medical Oncology Department, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain

  • Nebraska Cancer Specialists, Omaha, NE

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

  • Hospital Universitario Doce de Octubre, Madrid, Spain

Locations

  • Russia

  • Spain

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Enhancer of zeste homolog 2

Drug/Treatment

  • CB-7598

  • EZH2

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Expansion Study

Phase

  • I

Study Id's

  • NCT03460977<

  • NCT03460977

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved